Poxel and Enyo in second deal for FXR technology in infectious diseases
French diabetes focused biotech firm Poxel (Euronext: POXEL) saw its shares gain 4.6% to 8.89 euros this morning, after it announced a second agreement with Enyo Pharma, by which Enyo accesses a key patent on the use of FXR technology to develop treatments for hepatitis B.
The FXR Agonist technology was discovered and patented by Poxel together with academic partners represented by Inserm Transfert and the Lyon-based company EDELRIS. Inserm Transfert has been appointed to represent all parties in the patent agreement with Enyo. Enyo and Poxel signed a license agreement in May on Poxel’s FXR Agonist program for infection-related indications (The Pharma Letter May 7). No financial terms of either agreement have been disclosed.
“This agreement recognizes Poxel’s scientific insight in FXR agonists and allows the company to gain value for discoveries applicable outside our focus on type 2 diabetes. We are pleased to see Enyo further advance the FXR Agonist program,” commented Thomas Kuhn, chief executive of Poxel.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze